ADULT VACCINES MARKET ANALYSIS

Adult Vaccines Market, By Vaccines (Influenza, Tetanus, Diphtheria, Pertussis (Td/Tdap), Varicella, Human Papillomavirus, Zoster, Measles, Mumps, Rubella (MMR), Pneumococcal, Hepatitis, Others), By Vaccine Type (Monovalent and Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Viral/Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In April 2024, Merck, a pharmaceutical company, announced results from the Phase 3 trial STRIDE-10 at the 34th ESCMID Global in Barcelona, Spain. The trial assessed V116, Merck's 21-valent pneumococcal conjugate vaccine designed for adults. It compared V116's immunogenicity, tolerability, and safety with PPSV23 (23-valent pneumococcal polysaccharide vaccine) in adults aged 50 and older who had not previously been vaccinated against pneumococcal disease.
Pfizer Inc., a pharmaceutical company, received FDA approval for ABRYSVO (Respiratory Syncytial Virus Vaccine), its bivalent RSV prefusion F (RSVpreF) vaccine. This vaccine is designed to prevent lower respiratory tract disease caused by RSV in individuals aged 60 years and older. ABRYSVO consists of two preF proteins, chosen to enhance protection against both RSV A and B strains, and has been found to be safe and effective.
Sanofi, a pharmaceutical and healthcare company, announced that it had entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic coli (9-valent) developed by Janssen, currently in Phase 3. The agreement brings together Janssen’s robust science behind this potential first-in-class product and Sanofi’s worldwide manufacturing footprint and recognized world-class expertise in launching innovative vaccines.